On Jan. 04, Lamb Peter divested U.S. $1,320,800 in shares of Exelixis Inc.. The EVP, Scientific Strategy, CSO sold 65,000 shares at a price per share of $20.32. The transaction decreased this specific insider’s holdings to 300,229 shares worth around $6.56 million at present.
Barclays launched its Exelixis Inc. [EXEL] rating to the equivalent of an Overweight and assigned the price target of $26, in a research note dated March 04, 2020. That figure represents around a 15.92% premium from where the company’s shares closed on Wednesday. Some new analysts also started their coverage, with Barclays’s analysts assigning the shares to “an Overweight” rating in a research note to investors issued in early March. Meanwhile, SunTrust had launched its coverage on EXEL with “Buy”, in a research note produced for clients January 13, 2020. In addition, there was a new coverage from BofA/Merrill on November 13, 2019. The research firm rated EXEL “a Buy”.
Is Exelixis Inc. [NASDAQ:EXEL] a Good Buy Right Now?
It should be noted that EXEL technical indicators for short, intermediate as well as long term progress have placed an overall average of 24% as Sell. The average signal changed from 72% Sell in the last week and compares with 88% Sell in the past month. Data from Exelixis Inc.’s Trend Spotter indicated that the signals were Strongest. The stock current average is 2.48 million shares in the past 20 days and the short term average signal indicates a Hold. In the last 50 days, the average trading volume was 2.21 million shares while the medium term average advocated for 50% Sell. The average long-term signal stands at 50% Sell and the 100-day average volume stands at 2.09 million shares.
EXEL Price Performance
On Wall Street, Exelixis Inc. [NASDAQ:EXEL] finished Wednesday’s session up 2.29% at $21.86. The stock went up to $22.23 at the same session while its lowest single day price was $21.15. In the last five days, it saw a rise of about 8.70%, Exelixis Inc. shares gained by almost 8.92% since the beginning of the year. However, the share price has dropped to as low as -21.37% below its one year high. On 01/06/21, the company shares recorded $22.23, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/04/21, the same year at $19.82. The company’s shares have inclined by 17.05% in the past year. The 50-day SMA achieved is $20.13 while the 200-day SMA is $22.29. Volume gained to 4.59 million from 3.16 million in the previous session.
Exelixis Inc. [EXEL] Valuation Measures
Notably, Exelixis Inc. [EXEL] stock cannot be classified as a good candidate in the listing of underestimated low-priced Biotechnology companies to purchase soonest possible with the prevailing 12-month PE ratio of 45.64. The measure means the stock is exchanging at a premium as compared to the 41.72x trailing earnings of the industry. It can be helpful for investors to consider historical price-sales ratio, more specifically, a 7.10 PS value ratio is reported for the last one year of reported earnings. That is lower than the industry average of 20.33 which means EXEL serve an unattractive investment opportunity compared to its competitors.
EXEL Stock Support And Resistance Levels
On the 24-hour scale, the immediate backing is perceived around 21.26 level, and in case of violation of this particular level, it will cause more drop to 20.67 level. On the upper level, 22.83 is still the key resistance. The stock may increase to the subsequent resistance at 22.34. The Relative Strength Index (RSI) pinned on the 14-day chart is 67.08, implying a neutral technical stance while the MACD stands at 0.80, meaning price will decrease in the next trading period. Percent R indicator moved to 12.46%, implying bullish price movement. Stochastic %K at 85.11% suggest selling the stock.
What is the short interest in Exelixis Inc.?
Short interest in the Exelixis Inc. stock has plunged, decreasing by -0.76 million shares to total 14.38 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 13.62 million, data from Yahoo Finance shows. The increase of 5.29% suggests the stock saw some increased bearish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 5.24% of the overall float for the stock.
Exelixis Inc.’s Biggest Shareholders: Who Owns Exelixis Inc. [EXEL]?
Filings by BlackRock Fund Advisors showed that the firm now holds a total of 27,708,329 shares or roughly 8.93% of the outstanding EXEL shares. This means their shares have reduced by -970,294 from the 27,708,329 the investor reportedly held in its prior 13-F filing. With the conclusion of the sale, The Vanguard Group, Inc. updated stake is worth $523,830,032. Details in the latest 13F filings reveal that Renaissance Technologies LLC disposed off their -1.48% stake valued at $434,273,088 while T. Rowe Price Associates, Inc. added theirs at $261,366,714. During the last quarter, Renaissance Technologies LLC liquidated -341,300 of its shares in Exelixis Inc. while T. Rowe Price Associates, Inc. bought 177,136 shares. The Meditor Capital Management Ltd.’s holdings currently number 12,841,798 shares at $280721704.28. According to the firm’s last 13F report, Fidelity Management & Research Co shares in the company at filing stood at 12,053,587 shares, roughly $230,946,727.
EXEL Earnings Forecast For The Current Quarter
Exelixis Inc. [EXEL] is expected to report weak earnings results for the quarter ending on Dec 2020. Consensus estimates give the company expected revenues of $213.78M and an earnings per share of -$0.07 for Dec 2020. Looking further ahead, the company is expected to report revenue of $246.36M at an EPS of $0 for Mar 2021. The estimates represent downside of 24.40% and 120.77% in the company’s revenue and earnings per share, respectively, on a year-on-year basis.
EXEL Earnings Estimates For The Current Year
For the financial year, Exelixis Inc. [NASDAQ:EXEL] is expected to bring in revenue of $930.93M. The returns are nearly $-36.85 million lower than the company’s actual revenue recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at 0.19, lower than that of FY19 by -$0.83. Estimates put this year’s earnings growth at -81.40%, 115.80% for the next, and at an annual 46.00% over the next 5-year period. As for sales, forecasts are for a decrease of -3.80% in the current fiscal year and a further 24.40% over the following year.
What are analyst thoughts on Exelixis Inc.?
Looking forward to the Exelixis Inc. share price prediction, we can see that analysts, surveyed by FactSet, offer the mean price target for Exelixis Inc. stock at $30.00 within the next 12 months, which represents almost 27.13 per cent growth from its previous closing price of $21.86. The highest analysts’ target for Exelixis Inc. stock projections is $40.00 and the lowest one is $25.00. Still, 12 analysts sharing their consensus rating for EXEL stock in 2021 agree that it is an Overweight.